Your Health, We Care
Release date: 2026-05-06 13:52:09 Article From: Lucius Laos Recommended: 14
The recommended daily dose and maximum daily dose of this product is 20 mg once daily as one tablet. The starting dose depends on your kidney function: the doctor will decide whether to start with 20 mg or 10 mg based on blood test results. After 4 weeks of treatment, the doctor will test your blood again and determine the appropriate maintenance dose for you (either 20 mg or 10 mg). The doctor may also advise you to interrupt or stop treatment based on blood test results. Take orally at the same time each day. Swallow the tablet whole with water, with or without food. Do not take with grapefruit juice. If you cannot swallow the tablet whole, you may crush it and mix it with water or soft food (e.g., applesauce) and take it immediately. If you forget a dose: take it as soon as you remember on the same day; if you miss a full day, take the next tablet at the usual time the following day. Do not double the dose. Do not stop taking the medicine without your doctor's advice.
This medicine may cause adverse reactions. A very common adverse reaction (affecting more than 1 in 10 people) is hyperkalemia, possible signs of which include weakness or fatigue, nausea, numbness in hands and feet, muscle cramps, slow heart rate. Common adverse reactions (affecting up to 1 in 10 people) include: hyponatremia (signs: nausea, fatigue, headache, confusion, muscle weakness or cramps), decreased glomerular filtration rate, hyperuricemia, and hypotension (signs: dizziness, lightheadedness, fainting) and pruritus. Uncommon adverse reactions (affecting up to 1 in 100 people) include decreased hemoglobin. If you experience adverse reactions, tell your doctor or pharmacist, or you may also report them directly to the Danish Medicines Agency.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date (EXP) stated on the packaging. The expiry date refers to the last day of that month. This medicine does not require any special storage conditions.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：3002025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：5172024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3002025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：3142025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2882025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3412025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2922025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2702025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
